Muscle Weakness
Systemic Therapies
Clinical Presentation
Pathogenesis
Epidemiology
Introduction to Dermatomyositis
Dazukibart shows promise as treatment for dermatomyositis
Dazukibart, a type I interferon inhibitor, reduced dermatomyositis disease severity while maintaining a well-tolerated safety profile among patients, according to a study.
FDA grants fast-track designation to myotonic dystrophy type 1 treatment
The FDA has granted fast-track designation to an investigational antisense oligonucleotide to treat individuals with myotonic dystrophy type 1, or DM1, according to the manufacturer.
Phase 3 enrollment completed for study evaluating brepocitinib in dermatomyositis
Enrollment in the phase 3 VALOR study evaluating brepocitinib for the treatment of dermatomyositis has been completed, Priovant Therapeutics announced in a press release.
Statin use when not indicated for certain strokes could cause adverse events
Statin initiation in patients with stroke etiologies not indicated for secondary prevention with statin therapy could hypothetically cause thousands of adverse events every year, according to a new meta-analysis published in Stroke.
Inspiratory muscle training improves muscle endurance, dyspnea following COVID-19
SAN DIEGO — Individuals with inspiratory muscle weakness 2 years after COVID-19 hospitalization had improvement with inspiratory muscle training, according to research presented at the American Thoracic Society International Conference.